Compare GSK plc (GSK) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NetEase Inc — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while NetEase Inc trades at $124.97 (market cap $82.75B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | NTES | |
|---|---|---|
Market Cap | $102.60B | $82.75B |
Sector | Health | Media |
52-Week High | $61.18 | $159.34 |
52-Week Low | $38.22 | $109.26 |
Enterprise Value | $123.04B | $59.05B |
Dividend Yield | 3.57% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
NetEase (NTES) trades at $124.08, down 6.99% over the past 24 hours, with a P/E ratio of 16.31 and strong profitability metrics including a 29.84% net income margin. Recent earnings show mixed results with a Q1 2026 beat but Q3 and Q4 2025 misses. Technical indicators suggest a bullish trend with support at $126 and resistance at $129. The company maintains robust cash flow from operations of $50.74 billion in 2025 and recently announced a $0.72 dividend for H1 2026.
Outlook remains positive with 82% analyst buy ratings and a projected 34.7% upside potential. Key opportunities include international expansion and strong free cash flow generation, while risks involve competitive pressures in gaming and regulatory uncertainties in China. Revenue growth is steady, reaching $112.63 billion in 2025, supporting a solid fundamental base for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
